Novo Nordisk stock will ride a wave of demand for Ozempic pills in 2026.

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of ...

Gene therapy for weight loss is being explored as a potential game-changer, with therapy aiming to program the body to ...

Morning! Today, we see a new synthetic biology startup, backed by Frances Arnold and Bob Langer. Plus, it’s still early, but Novo Nordisk already appears to be having a robust rollout of the Wegovy ...

The pill version of Wegovy seems to work just as well as the injectable form, but there are some key differences between the ...

Dr. Reddy’s has received an approval from India’s drug regulator to manufacture and sell the generic version of diabetes drug ...

The patent for Semaglutide, the active ingredient in Novo Nordisk's drugs Wegovy and Ozempic, expires in March 2026, allowing ...

Your premium access has ended, but the best of Nation.Africa is still within reach. Renew now to unlock exclusive stories and in-depth features. Reclaim your full access. Click below to renew.

We look at the Novo Nordisk A/S outlook for 2026: new CEO focus, oral Wegovy edge vs Eli Lilly, and double-digit growth ...

Indian drugmaker Dr Reddy's , which reported a smaller-than-expected fall in quarterly profit on Wednesday, said that it has received an approval from the country's drug regulator to manufacture and ...

India, meanwhile, witnessed the launch of three global obesity blockbusters last year—Mounjaro, Wegovy, and Ozempic (approved for type-2 diabetes but widely used off-label for obesity). All three have ...